Back to top
more

Regeneron Pharmaceuticals (REGN)

(Real Time Quote from BATS)

$831.67 USD

831.67
342,620

+15.02 (1.84%)

Updated Nov 7, 2024 12:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sanofi's (SNY) Dupixent Meets Goal in Pivotal COPD Study

by Zacks Equity Research

Sanofi (SNY) and partner Regeneron's (REGN) Dupixent led to a 30% decline in exacerbations per a late-stage pivotal study on chronic obstructive pulmonary disease.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Regeneron (REGN) Gets Label Extension for Cholesterol Drug

by Zacks Equity Research

Regeneron (REGN) gets FDA approval for Evkeeza to treat children aged 5 to 11 with homozygous familial hypercholesterolemia.

Regeneron (REGN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Regeneron (REGN) closed the most recent trading day at $759.76, moving +0.07% from the previous trading session.

Sanofi's (SNY) Dupixent Gets EU Nod for Eczema in Young Kids

by Zacks Equity Research

Sanofi (SNY) and Regeneron's Dupixent becomes the first and only targeted medicine approved to treat severe atopic dermatitis in kids as young as six months old in Europe.

Regeneron (REGN) Gains 9.3% in a Year: Will the Uptrend Last?

by Zacks Equity Research

Regeneron (REGN) has had a good run in the past 12 months and the momentum should continue in 2023 on the back of growth in Dupixent, as Eylea faces challenges.

Regeneron (REGN) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Regeneron (REGN) closed at $760.30, marking a -0.85% move from the previous day.

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

The Zacks Analyst Blog Highlights NVIDIA, McDonald's, Intuit, AT&T and Regeneron Pharmaceuticals

by Zacks Equity Research

NVIDIA, McDonald's, Intuit, AT&T and Regeneron Pharmaceuticals are part of the Zacks top Analyst Blog

Sheraz Mian headshot

Top Analyst Reports for NVIDIA, McDonald's & Intuit

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), McDonald's Corporation (MCD) and Intuit Inc. (INTU).

Regeneron (REGN) Stock Moves -0.19%: What You Should Know

by Zacks Equity Research

Regeneron (REGN) closed the most recent trading day at $743.75, moving -0.19% from the previous trading session.

Sanofi (SNY), Regeneron Dupixent sBLA Accepted for FDA Review

by Zacks Equity Research

Sanofi's (SNY) sBLA seeking label expansion of drug Dupixent for chronic spontaneous urticaria accepted by the FDA

Biotech Stock Roundup: MRNA Q4 Earnings, REGN's Updates, CYTK Receives Setback

by Zacks Equity Research

Earnings from Moderna (BIIB) and updates from Regeneron (REGN) are the key highlights from the biotech sector during the past week.

Bayer's (BAYRY) Q4 Earnings and Revenues Top, Outlook Weak

by Zacks Equity Research

Bayer (BAYRY) beats on earnings and sales in the fourth quarter. However, its 2023 outlook is dismal.

Intellia's (NTLA) Q4 Loss Matches Estimates, Revenues Up Y/Y

by Zacks Equity Research

Intellia Therapeutics (NTLA) reports loss for fourth-quarter 2022, in line with estimates.

Alnylam (ALNY) Q4 Earnings Top, Product Sales Boost Revenues

by Zacks Equity Research

Alnylam Pharmaceuticals (ALNY) reports better-than-expected fourth-quarter 2022 results. Total revenues of the company continue to be driven by the sales of Onpattro, Givlaari, Oxlumo and the newly approved Amvuttra.

Regeneron (REGN) Rare Disease Drug Gets FDA's Priority Review

by Zacks Equity Research

Regeneron's (REGN) application seeking approval of pozelimab for the ultra-rare hereditary immune disease CHAPLE gets Priority Review by the FDA.

Sanghamitra Saha headshot

5 Least-Hurt Biotech ETFs of the Last Week

by Sanghamitra Saha

Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.

Regeneron's (REGN) Eylea Gets FDA Nod for ROP in Infants

by Zacks Equity Research

Regeneron's (REGN) Eylea gets FDA approval for the treatment of preterm infants with retinopathy of prematurity (ROP).

Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update

by Zacks Equity Research

Earnings results from Amgen (AMGN), Gilead (GILD) and others are the key highlights from the biotech sector during the past week.

Compared to Estimates, Regeneron (REGN) Q4 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Regeneron (REGN) Q4 Earnings & Sales Beat, Eylea Sales Decline

by Zacks Equity Research

Regeneron (REGN) tops earnings and sales estimates for the fourth quarter. However, sales of the lead drug Eylea decline year over year.

Sanofi (SNY) Q4 Earnings Miss Estimates, Vaccine Sales Weak

by Zacks Equity Research

Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. Higher sales of Dupixent and other specialty medicines were offset by a decline in vaccine sales.

Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Regeneron (REGN) delivered earnings and revenue surprises of 29.75% and 7.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Roche's (RHHBY) 2022 Core Earnings Grow, 2023 Outlook Dismal

by Zacks Equity Research

Roche's (RHHBY) performance in 2022 was sub-par as demand for COVID-19-related products declined significantly and 2023 will also be impacted.